# A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents

> **NCT03813238** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 63 (actual)

## Conditions studied

- Cerebral Palsy, Dyskinetic

## Interventions

- **DRUG:** TEV-50717
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03813238
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-06
- **Primary completion:** 2022-07-05
- **Final completion:** 2022-07-21
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2023-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03813238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03813238, "A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03813238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*